Chemotherapy improves survival rate in Stage 1 ovarian cancers

Purpose of Investigation: The role of adjuvant chemotherapy in Stage 1 ovarian cancer is conflicting with no clear evidence to support adjuvant chemotherapy versus observation alone. The authors sought to establish the survival benefit of adjuvant chemotherapy in all Stage 1 ovarian cancers. Materials and Methods: Retrospective data including age, stage, grade, histology, RMI, and chemotherapy status on all patients undergoing treatment for Stage 1 ovarian cancer between May 2003 and November 2013 at Royal Derby Hospital was collected. Results: Eighty-nine cases of Stage 1 ovarian cancer were included. A total of 73 patients (84.88%) received adjuvant chemotherapy while 13 (15.12%) did not. The patients receiving adjuvant chemotherapy had a median overall survival (OS) of 108 months (CI 99.07−118.33) while the median OS for the patients who did not receive any adjuvant treatment was 63.71 months (CI 43.06−83.35) p = 0.003. Conclusion: Adjuvant chemotherapy significantly improves OS in Stage 1 ovarian cancer patients.

Ovarian cancer; Stage 1; Adjuvant; Chemotherapy.

[1] UK Cancer Research, 2015. Available at: http://www.cancerresearchuk. org/health-professional/cancer-statistics/statistics-bycancer-type/ovarian-cancer/incidence - heading-Zero.

[2] NICE Clinical Guideline 122: The recognition and initial management of ovarian cancer. 2011: Cardiff (UK). Available at:

https://www.nice.org.uk/Guidance/CG122

[3] Winter-Roach B.A., Kitchener H.C., Lawrie T.A.: Adjuvant (postsurgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst. Rev., 2012, 3, CD004706.

[4] Colombo N., Pecorelli S.: “What have we learned from ICON1 and ACTION?” Int. J. Gynecol. Cancer, 2003, 13, 140.

[5] Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., et al.: “International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”. J. Natl. Cancer. Inst., 2003, 95, 105.

[6] Collinson F., Qian W., Fossati R., Lissoni A., Williams C., Parmar M., et al.: “Optimal treatment of early-stage ovarian cancer”. Ann. Oncol., 2014, 25, 1165.

[7] Ovarian Cancer National Alliance: “Risk factors”. 2015. Available at: http://www.ovariancancer.org/about/risk-factors/

[8] Vergote, I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P. “Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma”. Lancet, 2001, 357, 176.

[9] Winter-Roach B.A., Kitchener H. C., Lawrie T.A.: “Adjuvant (post-postsurgery) chemotherapy for early stage epithelial ovarian cancer”. Cochrane Database Syst. Rev., 2015, 12, CD004706.